Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.

Signal transduction and targeted therapy - 5 Mar 2026

Lim Jung Hwa, Mun Seon Ju, Kang Hyun Mi, Yu Won Dong, Oh Soo Jin, Lee Ji-Yoon, Son Ye Seul, Lee Sugi, Kim Dae Soo, Lee Jaeseo, Kim Su Jeong, Cho Hyun-Soo, Son Myung Jin, Son Mi-Young, Jung Cho-Rok

Abstract excerpt

Effective precision oncology demands integration of pharmacokinetics/pharmacodynamics (PK/PD) profiling with tumor-specific genomic features. Here, we present a personalized treatment model using a patient-derived Networking Organoid Culture System (NOCS) composed of intestinal, liver, and kidney organoids differentiated from induced pluripotent stem cells (iPSCs) of an NF1-mutant breast cancer patient. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to NF1 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induced Pluripotent Stem Cells

Share to Mutation

Share to Neurofibromin 1

Share to Organoids

Share to Precision Medicine

Source

Open in PubMed Open full text

Identifiers

PMID: 41781386
DOI: 10.1038/s41392-026-02595-7
PMCID: PMC12960935

Genes

NF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized pharmacokinetic-pharmacodynamic guided therapy via an induced pluripotent stem cell-derived multi-organoid platform in NF1-mutant breast cancer.PMID 41781386Read ↗

Systematic functional drug testing in patient-derived models reveals ex vivo sensitivities associated with clinical outcome in rare solid tumorsSemantic proximity Read ↗

Functional Drug Screening in the Era of Precision MedicineSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

Patient-derived urachal cancer organoids for personalized drug screeningSemantic proximity Read ↗

Molecular Oncodiagnostics in Precision Oncology: Integrating Tumor Transcriptomics, Patient Pharmacogenetics, and Ex Vivo Chemoresistance Testing to Improve Individual Chemotherapy ResponseSemantic proximity Read ↗

Pancreatic cancer patient-derived organoids capture therapy response and tumor evolutionSemantic proximity Read ↗

Transforming cancer treatment: integrating patient-derived organoids and CRISPR screening for precision medicineSemantic proximity Read ↗

Enhancing precision medicine for patients with breast cancer brain metastases through functional drug testingSemantic proximity Read ↗

Targeting cancer drug resistance utilizing organoid technologySemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

The landscape of drug sensitivity and resistance in sarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.